Premium
P4‐257: SUVN‐G1031, a novel selective H3 receptor antagonist in animal models of cognitive deficits
Author(s) -
Jayarajan Pradeep,
Shanmuganathan Dhanalakshmi,
Jabaris Sugin Lal,
Babu Medapati Rajesh,
Baburao Kancharla,
Mohanty Swayam Sampurna,
Kandikere Vishwottam,
Muddageswararao,
Saralaya Ramanatha,
Budige Ganesh,
Ahmad Ishtiyaque,
Mekala Venkat Reddy,
Garikapati Ram Mohan,
Faheem Mohammed Abdul,
Shinde Anil,
Deshpande Amol,
Rambabu Namala,
Nirogi Ramakrishna
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.2282
Subject(s) - histamine h3 receptor , morris water navigation task , neuroscience , receptor antagonist , psychology , antagonist , nmda receptor , pharmacology , chemistry , medicine , receptor , cognition
26 of them completed the study. Electrocardiogram (ECG) records werereceived at the baseline and at the each dose of rivastigmine patch therapy (5cm2, and 10 cm2 respectively), and also blood pressure was measured baseline. Results: We studied 15 male and 11 female elderly subjects (mean age 78.2 6 7.6) with newlydiagnosed LOAD. Mean 6 SD valuesof heart rates are 72 6 15, 666 10, and 67 6 10,PR intervals are 171 6 224, 1786 21,and 1726 28, QRS durations are 886 17, 926 14 and 896 15, QT intervals are 393 6 41,411 6 31 and 408 6 33, and QTc intervals are 421 6 17, 426 6 12 and 426 6 21 (at baseline,5 cm, and 10 cm, respectively). Over two four-week each dose of rivastigmine treatment periods, there were no significant change in all ECG parameters when compared with baseline ECG parameters (Figure, table). Conclusions: According to these results, it is clear that the usual dosage of rivastigmine patch seems to be safe for elderly patients. Nevertheless,it is recommended that these patients are closely monitored for electrocardiographic changes during therapy.